Aligos Therapeutics Ownership
| ALGS Stock | USD 17.33 0.49 2.75% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 3.1 M | Current Value 6.3 M | Avarage Shares Outstanding 27 M | Quarterly Volatility 15 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Aligos |
Aligos Stock Ownership Analysis
About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aligos Therapeutics recorded a loss per share of 7.25. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 19th of August 2024. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more info on Aligos Therapeutics please contact Dr MBA at 800 466 6059 or go to https://www.aligos.com.Besides selling stocks to institutional investors, Aligos Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Aligos Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Aligos Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Aligos Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Aligos Therapeutics Insider Trades History
About 18.0% of Aligos Therapeutics are currently held by insiders. Unlike Aligos Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Aligos Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Aligos Therapeutics' insider trades
Aligos Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aligos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aligos Therapeutics backward and forwards among themselves. Aligos Therapeutics' institutional investor refers to the entity that pools money to purchase Aligos Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-12-31 | 23 K | Drive Wealth Management, Llc | 2024-12-31 | 23 K | Wells Fargo & Co | 2024-12-31 | 21.8 K | Ubs Group Ag | 2024-12-31 | 15.5 K | Charles Schwab Investment Management Inc | 2024-12-31 | 14.3 K | Blackrock Inc | 2024-12-31 | 13.7 K | Renaissance Technologies Corp | 2024-12-31 | 11.4 K | State Street Corp | 2024-12-31 | 9.6 K | Northern Trust Corp | 2024-12-31 | 5.2 K | Adage Capital Partners Gp Llc | 2024-12-31 | 325 K | Ecor1 Capital, Llc | 2024-12-31 | 255.6 K |
Aligos Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aligos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aligos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aligos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aligos Therapeutics Outstanding Bonds
Aligos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aligos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aligos bonds can be classified according to their maturity, which is the date when Aligos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ATDBCN 3625 13 MAY 51 Corp BondUS01626PAQ90 | View | |
| ATDBCN 45 26 JUL 47 Corp BondUS01626PAG19 | View | |
| ATDBCN 355 26 JUL 27 Corp BondUS01626PAH91 | View | |
| ATDBCN 295 25 JAN 30 Corp BondUS01626PAM86 | View | |
| ATDBCN 38 25 JAN 50 Corp BondUS01626PAN69 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Aligos Therapeutics Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 12th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.